MY165953A - Methods and compositions for treating inflammation and ischemic injury - Google Patents

Methods and compositions for treating inflammation and ischemic injury

Info

Publication number
MY165953A
MY165953A MYPI2014001446A MYPI2014001446A MY165953A MY 165953 A MY165953 A MY 165953A MY PI2014001446 A MYPI2014001446 A MY PI2014001446A MY PI2014001446 A MYPI2014001446 A MY PI2014001446A MY 165953 A MY165953 A MY 165953A
Authority
MY
Malaysia
Prior art keywords
methods
compositions
cysteamine
derivative
ischemic injury
Prior art date
Application number
MYPI2014001446A
Other languages
English (en)
Inventor
Ranjan Dohil
Susan A Phillips
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MY165953A publication Critical patent/MY165953A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MYPI2014001446A 2011-11-22 2012-11-21 Methods and compositions for treating inflammation and ischemic injury MY165953A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161563034P 2011-11-22 2011-11-22

Publications (1)

Publication Number Publication Date
MY165953A true MY165953A (en) 2018-05-18

Family

ID=47297472

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2014001446A MY165953A (en) 2011-11-22 2012-11-21 Methods and compositions for treating inflammation and ischemic injury

Country Status (16)

Country Link
US (1) US20140322315A1 (OSRAM)
EP (1) EP2782564B1 (OSRAM)
JP (1) JP6411215B2 (OSRAM)
KR (1) KR20140097132A (OSRAM)
CN (2) CN103974698A (OSRAM)
AU (1) AU2012340670B2 (OSRAM)
BR (1) BR112014012167A2 (OSRAM)
CA (1) CA2851387A1 (OSRAM)
HK (1) HK1202440A1 (OSRAM)
IL (1) IL232608A0 (OSRAM)
MX (1) MX2014004469A (OSRAM)
MY (1) MY165953A (OSRAM)
RU (1) RU2638807C2 (OSRAM)
SG (2) SG11201402472QA (OSRAM)
WO (1) WO2013078335A1 (OSRAM)
ZA (1) ZA201402290B (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR096628A1 (es) * 2013-06-17 2016-01-20 Raptor Pharmaceuticals Inc Formulación en perlas de cisteamina de liberación retardada y métodos de preparación y uso de ella
AU2016288230A1 (en) 2015-07-02 2018-01-25 Horizon Orphan Llc ADO-resistant cysteamine analogs and uses thereof
CN106591461A (zh) * 2016-12-29 2017-04-26 天津协和华美医学诊断技术有限公司 一种检测遗传性易栓症相关基因群的检测试剂盒
US11020354B2 (en) 2017-01-19 2021-06-01 Otologic Pharmaceuticals, Inc. Formulations of n-acetylcysteine and uses thereof
WO2018140594A1 (en) * 2017-01-25 2018-08-02 Adare Pharmaceuticals, Inc. Cysteamine prodrugs
WO2021022012A1 (en) * 2019-07-30 2021-02-04 The Regents Of The University Of California Methods and composition for treating respiratory obstructive diseases
CN113484453B (zh) * 2021-07-07 2022-08-09 天津中医药大学 一种缺血性脑卒中预警方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4301146A (en) 1980-07-29 1981-11-17 G. D. Searle & Co. Stabilization of 16-oxygenated prostanoic acid derivatives
FR2549051B1 (fr) 1983-06-22 1986-05-16 Centre Nat Rech Scient Nouveaux agents radioprotecteurs ayant une structure amino-thioalkyle et procede pour leur preparation
FR2573077B1 (fr) * 1984-11-13 1987-02-13 Sanofi Sa Nouveaux derives thiosulfonates, leur procede de preparation ainsi que les compositions pharmaceutiques les contenant
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
EP0306937A3 (en) * 1987-09-08 1990-07-25 The Green Cross Corporation Platelet agglutination-inhibiting agent
JPH02243619A (ja) * 1989-03-15 1990-09-27 Green Cross Corp:The 抗血小板凝集剤
SK232890A3 (en) 1989-05-17 1998-11-04 Pfizer 2-piperidino and 2-pyrrolidino-1-alkanols derivatives and preparation method thereof
US5225202A (en) 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
US5436255A (en) 1992-07-23 1995-07-25 Pfizer Inc. Method of treating diseases susceptable to treatment by blocking NMDA-receptors
TW281670B (OSRAM) 1993-09-02 1996-07-21 Hoffmann La Roche
WO1997023202A1 (en) 1995-12-22 1997-07-03 STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITYA ND THE UNIVERSITY OF OREGON, EUGENE OREGON Subtype-selective nmda receptor ligands and the use thereof
ZA9610736B (en) 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
US6087398A (en) * 1996-03-01 2000-07-11 South Alabama Medical Science Foundation Sickle cell anemia treatment
FR2753098B1 (fr) * 1996-09-06 1998-11-27 Sod Conseils Rech Applic Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene
DE19643790A1 (de) 1996-10-30 1998-05-07 Merck Patent Gmbh Benzoxazol-Derivat
KR20010024548A (ko) 1997-10-24 2001-03-26 로즈 암스트롱 질병관련 또는 약물유발 운동장해의 치료방법
PE20000728A1 (es) 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
WO2000025109A1 (en) 1998-10-28 2000-05-04 Scofield Dillon F Electrodynamic particle size analyzer
US6489477B1 (en) 1999-10-29 2002-12-03 Merck & Co., Inc. 2-aza-bicyclo[2.2.2]octane NMDA/NR2B antigonists
US6316474B1 (en) 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
US6369076B1 (en) 1999-10-29 2002-04-09 Merck & Co. Inc. 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
US6432976B1 (en) 1999-10-29 2002-08-13 Merck & Co., Inc. 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
US6291499B1 (en) 1999-10-29 2001-09-18 Merck & Co., Inc. 2-cyclohexyl benzimidazole NMDA/NR2B antagonists
AU1153601A (en) 1999-10-29 2001-05-08 Merck Sharp & Dohme Limited Method to treat pain utilizing benzimidazole NMDA NR2B antagonists
RU2367423C2 (ru) * 2003-12-19 2009-09-20 ОМЕГА БИО-ФАРМА (Ай.Пи. 3) ЛИМИТЕД Композиции и способы для лечения диабета
JP4976281B2 (ja) * 2004-05-03 2012-07-18 オメガ バイオ‐ファーマ（アイ．ピー．３）リミテッド 代謝を調節するための材料および方法
ES2417179T3 (es) * 2007-11-30 2013-08-06 The Regents Of The University Of California Métodos para tratar la esteatohepatitis no alcohólica (EHNA) mediante productos basados en cisteamina
RU2428192C1 (ru) * 2010-06-10 2011-09-10 Войсковая Часть 41598 Радиозащитное средство

Also Published As

Publication number Publication date
CA2851387A1 (en) 2013-05-30
JP2014533701A (ja) 2014-12-15
AU2012340670B2 (en) 2016-12-22
EP2782564A1 (en) 2014-10-01
RU2014125282A (ru) 2015-12-27
IL232608A0 (en) 2014-06-30
HK1202440A1 (zh) 2015-10-02
CN108042517A (zh) 2018-05-18
AU2012340670A1 (en) 2014-04-17
RU2638807C2 (ru) 2017-12-15
KR20140097132A (ko) 2014-08-06
US20140322315A1 (en) 2014-10-30
ZA201402290B (en) 2017-06-28
EP2782564B1 (en) 2019-01-09
SG11201402472QA (en) 2014-06-27
CN103974698A (zh) 2014-08-06
BR112014012167A2 (pt) 2017-05-30
JP6411215B2 (ja) 2018-10-24
SG10201800159QA (en) 2018-02-27
WO2013078335A1 (en) 2013-05-30
MX2014004469A (es) 2014-08-01

Similar Documents

Publication Publication Date Title
ZA202208792B (en) Methods of treating and preventing graft versus host disease
MY165953A (en) Methods and compositions for treating inflammation and ischemic injury
WO2014035140A3 (en) Compounds and compositions for modulating histone methyltransferase activity
CR20150216A (es) Composiciones y métodos para tratar proteinopatías
MX2018006578A (es) Formulaciones farmaceuticas topicas para tratar afecciones inflamatorias.
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
MX2017000307A (es) Tratamiento de leucemia con inhibidores de histona deacetilasa.
ECSP10010007A (es) Tratamiento con ligandos alpha-7-selectivos
MX388380B (es) Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes.
ZA201600453B (en) Compositions, methods and kits for diagnosing and treating cd206 expressing cell-related disorders
MX2021008281A (es) Estimuladores de guanilato ciclasa soluble (sgc).
MX2017003933A (es) Metodos de tratamiento de la enfermedad hepatica.
UY34332A (es) Composiciones y métodos para controlar malezas co mprendiendo un polinucleótido y agente de transfe rencia, y que modulan la fitoeno desaturasa?.
MX372990B (es) Composiciones para el tratamiento del ojo seco.
PH12015502091A1 (en) Cdc7 inhibitors
CR20150047A (es) Anticuerpos anti-cd22 e inmunoconjugados
EP3054954A4 (en) Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin&#39;s lymphoma
SI3220916T1 (sl) Postopek zdravljenja raka z n-((4,6-dimetil-2-okso-1,2-dihidropiridin-3 -il)metil)-5-(etil(tetrahidro-2h-piran-4-il) amino)-4-metil-4&#39;- (morfolinometil)-(1,1&#39;-bifenil)-3-karboksamidom
MX2020000467A (es) Compuestos retinoides y rexinoides inmunomoduladores en combinacion con inmunomoduladores para inmunoterapia contra cancer.
MX389020B (es) Metodos para tratar y evitar enfermedad cronica de injerto versus anfitrion impulsada por aloanticuerpo.
MX2015017253A (es) Composiciones y metodos para tratar trastornos metabolicos.
WO2015017529A3 (en) Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
MX359181B (es) Hidrolizado de colágeno y uso del mismo.
UY34070A (es) Método y composición para tratamiento de semillas.
MX2019007354A (es) Metodos para tratar trastornos de hiperpigmentacion.